Exelixis (EXEL) Releases Earnings Results, Beats Expectations By $0.11 EPS

Exelixis (EXEL) reported quarterly earnings results on Wednesday, Aug-3-2016. The company said it had a profit of $-0.16 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.11. Analysts had a consensus of $-0.27. The company posted revenue of $36.25 million in the period, compared to analysts expectations of $16.37 million. The company’s revenue was up 353.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.22 EPS.

Many Wall Street Analysts have commented on Exelixis. Company shares were Reiterated by Leerink Partners on Jun 21, 2016 to “Outperform”, Firm has raised the Price Target to $ 10 from a previous price target of $8 .

Exelixis closed down -0.12 points or -1.29% at $9.15 with 50,15,326 shares getting traded on Tusday. Post opening the session at $9.31, the shares hit an intraday low of $9 and an intraday high of $9.34 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on May 11, 2016, Lance Willsey (director) purchased 60,000 shares at $4.96 per share price. According to the SEC, on Oct 19, 2015, Peter Lamb (EVP, Discovery Research & CSO) sold 51,549 shares at $5.80 per share price.

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive metastatic medullary thyroid cancer (MTC) in the United States. The Company’s other programs include metastatic renal cell carcinoma (mRCC) a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888 a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).


Leave a Reply

Exelixis - Is it time to Sell?

Top Brokerage Firms are advising their investors on Exelixis. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.